Content |
Owners
History
2023
Sentence - 7 years in prison for the former head for helping to withdraw funds from Rusnano abroad
In October 2024, the Khoroshevsky Court of Moscow sentenced Valery Glavatsky to seven years in prison in absentia, who was accused of complicity in a particularly large embezzlement and money laundering. Read more here.
Recovery of 825 million losses from owners and managers
On May 27, 2023, the Ninth Arbitration Court of Appeal confirmed the decision of the first instance, which recovered almost 825 million rubles in losses from the founders and former leaders of NTpharma.
The case in question involves the theft of funds allocated for the implementation of a project for the production and production of vaccines. NTpharma (a subsidiary of Rusnano) has a large number of intangible assets on its balance sheet, including expensive know-how, as well as Adevac-Flu, AdeLact and AdeVasc vaccines. The total value of assets is estimated at 824.5 million rubles.
However, in reality, the development of drugs Adevac-Flu and AdeLact was not carried out, which was confirmed by the decision of the Khoroshevsky District Court of January 27, 2020. And the registration of the AdeVasc vaccine by NTpharma was denied due to the fact that as a result of clinical trials, no reliable development of the drug's effectiveness compared to placebo was achieved, and positive trends in the therapeutic effect of the drug require further clinical study. Thus, the development of AdeVasc did not actually produce the expected results, despite the allocated funds for the implementation of this project.
The defendants in the case are the former heads of NTpharma Rustam Ataullakhanov and Evgeny Sultanov, as well as the founders of Prom-Bi, Sarsfield Ventures Limited and Caverton Private Capital Limited. According to the investigation, the management of NTpharma organized a network of shell companies managed by them (Medezrin LLC, Biokon LLC, Biomed Invest LLC, Biotestlab LLC, NPO Sintez LLC, Stroyproekt LLC, etc.), with which fictitious contracts were concluded for the implementation of research and construction work, the supply of equipment and other tangible values. Approximately 424 million rubles were stolen in this way.
2020: Company bankruptcy
On May 8, 2020, it became known that NTpharma filed a lawsuit for its own bankruptcy with the Moscow Arbitration Court. The statement dates back to April 30.
As Vademecum was told in Rusnano, the general director filed for bankruptcy of NTpharma due to "objective circumstances," namely, due to the lack of sources of cash receipt in the framework of ordinary financial and economic activities due to the unfinished investment cycle. In this regard, the company lost the opportunity to repay debts, which by May 2020 reached 2.9 billion rubles. The bulk of accounts payable falls on Rusnano, the state corporation said.
Rusnano considers the bankruptcy procedure a step towards the financial recovery of the project for the construction of a plant in Pereslavl-Zalessky in the Yaroslavl region. The company is counting on restructuring, during which it is planned to maintain promising developments, including the registration of the drug for the therapy of amyotrophic lateral sclerosis "AdeVask," which in December 2018 passed the second phase of clinical trials.
The project, which is being discussed at Rusnano, was focused on the production of a trivalent vaccine against influenza, as well as medicines. Rusnano has invested more than 1 billion rubles. It was supposed to exclude the trivalent influenza vaccine from the project due to the fact that a large number of analogues appeared, and rely on another development of NTpharma - AdeVask.
The founder of NTpharma Rustamo Ataullakhanov and the former general director of companies Evgeny Sultanov were suspects in a criminal embezzlement case opened by the Investigative Committee. We are talking about the allocation of a land plot and the issuance of a construction permit for NTpharma. The proceedings ended with house arrests of the defendants.[1]
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |